Sign in Subscribe

Amylyx Drug Cuts Dangerous Low Blood Sugar Episodes After Weight-Loss Surgery in Key Trial

Amylyx’s avexitide reduced severe low blood sugar episodes by 55% in a Phase 3 trial for post-bariatric hypoglycemia. First potential treatment nears FDA filing.

Amylyx Drug Cuts Dangerous Low Blood Sugar Episodes After Weight-Loss Surgery in Key Trial
"Amylyx co-CEOs Justin Klee (left) and Joshua Cohen (right)." Credit: Amylyx
Already have an account? Sign in.